Laman UtamaMLLCF • OTCMKTS
add
Molecular Partners AG
Tutup sebelumnya
$4.53
Julat tahun
$3.66 - $10.14
Permodalan pasaran
239.77J USD
Bilangan Purata
28.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
SWX
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 681.00K | -73.20% |
Perbelanjaan pengendalian | 4.41J | -0.38% |
Pendapatan bersih | -16.40J | -43.40% |
Margin untung bersih | -2.41K | -435.08% |
Pendapatan bagi setiap syer | -0.49 | — |
EBITDA | -14.00J | -8.64% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 143.62J | -30.49% |
Jumlah aset | 154.21J | -29.30% |
Jumlah liabiliti | 15.43J | -29.56% |
Jumlah ekuiti | 138.78J | — |
Syer tertunggak | 33.19J | — |
Harga kepada buku | 1.08 | — |
Pulangan pada aset | -22.46% | — |
Pulangan pada modal | -24.30% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -16.40J | -43.40% |
Tunai daripada operasi | -13.28J | -0.68% |
Tunai daripada pelaburan | 14.22J | -20.00% |
Tunai daripada pembiayaan | -301.00K | -1.01% |
Perubahan bersih dalam tunai | 66.00K | -98.72% |
Aliran tunai bebas | -8.09J | -4.19% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
162
